Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xoma Royalty Corporation (XOMA)

Xoma Royalty Corporation (XOMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 392,990
  • Shares Outstanding, K 11,916
  • Annual Sales, $ 52,150 K
  • Annual Income, $ 31,710 K
  • EBIT $ 14 M
  • EBITDA $ 17 M
  • 60-Month Beta 0.68
  • Price/Sales 7.56
  • Price/Cash Flow 58.02
  • Price/Book 4.88

Options Overview Details

View History
  • Implied Volatility 77.69% (+0.02%)
  • Historical Volatility 44.35%
  • IV Percentile 27%
  • IV Rank 26.64%
  • IV High 172.07% on 12/12/25
  • IV Low 43.42% on 08/18/25
  • Expected Move (DTE 13) 0.43 (1.29%)
  • Put/Call Vol Ratio 1.67
  • Today's Volume 16
  • Volume Avg (30-Day) 36
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 698
  • Open Int (30-Day) 1,014
  • Expected Range 32.56 to 33.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.19
  • Number of Estimates 3
  • High Estimate $0.50
  • Low Estimate $-0.16
  • Prior Year $0.06
  • Growth Rate Est. (year over year) +216.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.04 +31.71%
on 03/04/26
34.00 -3.00%
on 04/01/26
+6.77 (+25.83%)
since 03/02/26
3-Month
22.29 +47.96%
on 02/11/26
34.00 -3.00%
on 04/01/26
+4.99 (+17.83%)
since 01/02/26
52-Week
18.35 +79.71%
on 04/07/25
39.92 -17.38%
on 10/03/25
+13.20 (+66.73%)
since 04/02/25

Most Recent Stories

More News
XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s...

XOMA : 32.98 (-0.30%)
XOMAP : 26.48 (-1.01%)
XOMAO : 25.64 (-1.25%)
XOMA Royalty: Q4 Earnings Snapshot

XOMA Royalty: Q4 Earnings Snapshot

XOMA : 32.98 (-0.30%)
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

Portfolio receipts : • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties...

XOMA : 32.98 (-0.30%)
XOMAP : 26.48 (-1.01%)
XOMAO : 25.64 (-1.25%)
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results...

XOMA : 32.98 (-0.30%)
XOMAP : 26.48 (-1.01%)
XOMAO : 25.64 (-1.25%)
XOMA Royalty to Present at Investor Conferences in March

EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following...

XOMA : 32.98 (-0.30%)
XOMAP : 26.48 (-1.01%)
XOMAO : 25.64 (-1.25%)
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.

EMERYVILLE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role...

GBIO : 5.34 (-6.97%)
XOMA : 32.98 (-0.30%)
XOMAP : 26.48 (-1.01%)
XOMAO : 25.64 (-1.25%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 32.98 (-0.30%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 32.98 (-0.30%)
XOMA Royalty Announces CFO Transition

EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) announced today its Chief Financial Officer, Thomas Burns, will be stepping down from...

XOMA : 32.98 (-0.30%)
XOMAP : 26.48 (-1.01%)
XOMAO : 25.64 (-1.25%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of XOMA Royalty Corporation ("Xoma" or the "Company") (NASDAQ: XOMA). Such investors are advised...

XOMA : 32.98 (-0.30%)

Business Summary

XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE,...

See More

Key Turning Points

3rd Resistance Point 34.87
2nd Resistance Point 34.15
1st Resistance Point 33.56
Last Price 32.98
1st Support Level 32.25
2nd Support Level 31.53
3rd Support Level 30.94

See More

52-Week High 39.92
Last Price 32.98
Fibonacci 61.8% 31.68
Fibonacci 50% 29.14
Fibonacci 38.2% 26.59
52-Week Low 18.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.